This segment focuses on the research, development, and commercialization of in-vitro diagnostic kits for various infectious diseases, including human papillomavirus (HPV), sexually transmitted diseases (STDs), and hepatitis B virus (HBV). The company utilizes real-time PCR technology and genoarray diagnostic kits to provide accurate and timely diagnoses. Research and development efforts are focused on expanding the test menu and improving the sensitivity and specificity of the assays. The patient impact is significant, as early and accurate diagnosis enables timely treatment and reduces the spread of infectious diseases. The company's market positioning is strong in mainland China and expanding globally, with a focus on providing high-quality, affordable diagnostic solutions. Future opportunities include expanding into new infectious disease areas and developing point-of-care testing solutions. Regulatory compliance and clinical validation are critical aspects of this segment, ensuring the reliability and accuracy of the diagnostic tests. Partnerships with hospitals and medical institutes are essential for clinical trials and market access.

This segment is dedicated to the development and commercialization of diagnostic products for genetic diseases, including thalassemia and hearing loss susceptibility. The company employs genoarray diagnostic kits to identify genetic markers associated with these conditions. Research and development activities focus on improving the accuracy and efficiency of genetic testing, as well as expanding the range of detectable genetic mutations. The patient impact is substantial, as early detection allows for proactive management and treatment, improving patient outcomes. The company's market position is strengthened by its focus on providing comprehensive genetic screening solutions. Future opportunities include expanding into other genetic diseases and developing more advanced genetic testing technologies. Regulatory compliance and clinical validation are crucial for ensuring the reliability and accuracy of the tests. Partnerships with hospitals and research institutions are essential for clinical trials and market access.

This segment focuses on the development, manufacturing, and distribution of real-time PCR kits for the detection of COVID-19. The company's research and development efforts are focused on improving the sensitivity and specificity of the tests, as well as developing new testing formats and platforms. The company's products are used in clinical settings, research institutions, and for national screening programs. The patient impact is significant, as accurate and timely diagnosis is critical for controlling the spread of the virus and providing appropriate medical care. The company's market positioning is strong in China and other regions, with a focus on providing high-quality, reliable, and affordable diagnostic solutions. Future opportunities include developing tests for new variants and expanding into point-of-care testing. Regulatory compliance and clinical validation are critical aspects of this segment, ensuring the accuracy and reliability of the tests. Partnerships with healthcare providers and government agencies are essential for market access and distribution.

This segment involves the design, manufacturing, and sale of instruments and devices used in nucleic acid molecular diagnostics. The company offers a range of automated nucleic acid extraction systems, automated PCR analysis systems, flow-through hybridization systems, and fluorescent quantitative detection systems. Research and development activities focus on improving the automation, efficiency, and accuracy of these instruments. The patient impact is indirect but significant, as these instruments enable faster and more reliable diagnostic testing. The company's market positioning is enhanced by its ability to provide a complete diagnostic solution, including both reagents and instruments. Future opportunities include developing new instrument platforms and expanding into new diagnostic areas. Regulatory compliance and quality assurance are critical aspects of this segment, ensuring the safety and reliability of the instruments. Partnerships with diagnostic kit manufacturers and research institutions are essential for market access and product development.